Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)

NCT07404111 is registered in ClinicalTrials.gov with Kriya Therapeutics, Inc. as lead sponsor.

NCT NCT07404111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)
Lead sponsor
Kriya Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 1, 2026
Completion date
August 31, 2029
Enrollment
135 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease (ted)